RE:RE:Could This Be?Thanks all;
Your speculations are all plausible and your opinions are solid, except that "Big Pharma doesn't work this way." Wrong. Most with an R&D branch, divisions or separate LLCs have enormous budgets to buy fairly good speculative patents and process rights so they can either work independently or in collaboration with the creators to add to their pipeline. They often take a bath on failures but they always mitigate the risk.
IMHO, I agree with you that a buyout, or at minimum a new board management arrangement with a focus on the ultimate sale of KNE, are more likely scenarios than continuing with PPs to fund for more research in Winterpeg.
I'm just surprised that the 2-3 fluffy weak news bulletins before this got more traction on SP movement than this announcement.
In one way it's good...I could use a couple of weeks to find more funds and buy more....hopefully the news will continue to be missed by the pumping piranhas.
GLTA